[go: up one dir, main page]

WO2000070665A3 - Long lasting anti-angiogenic peptides - Google Patents

Long lasting anti-angiogenic peptides Download PDF

Info

Publication number
WO2000070665A3
WO2000070665A3 PCT/IB2000/000763 IB0000763W WO0070665A3 WO 2000070665 A3 WO2000070665 A3 WO 2000070665A3 IB 0000763 W IB0000763 W IB 0000763W WO 0070665 A3 WO0070665 A3 WO 0070665A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
angiogenic
modified
conjugates
long lasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000763
Other languages
French (fr)
Other versions
WO2000070665A2 (en
Inventor
Dominique P Bridon
Michele Rasamoelisolo
Karen Thibaudeau
Xicai Huang
Richard Beliveau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Priority to CA002373252A priority Critical patent/CA2373252C/en
Priority to EP00929748A priority patent/EP1171582A2/en
Priority to JP2000619018A priority patent/JP4209086B2/en
Priority to AU47748/00A priority patent/AU764103B2/en
Priority to TNTNSN00190A priority patent/TNSN00190A1/en
Priority to SM200000031A priority patent/SM200000031A/en
Publication of WO2000070665A2 publication Critical patent/WO2000070665A2/en
Publication of WO2000070665A3 publication Critical patent/WO2000070665A3/en
Anticipated expiration legal-status Critical
Priority to US11/350,703 priority patent/US7741286B2/en
Priority to US12/759,153 priority patent/US20110071082A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
PCT/IB2000/000763 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides Ceased WO2000070665A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002373252A CA2373252C (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides
EP00929748A EP1171582A2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides
JP2000619018A JP4209086B2 (en) 1999-05-17 2000-05-17 Long-lasting anti-angiogenic peptide
AU47748/00A AU764103B2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides
TNTNSN00190A TNSN00190A1 (en) 2000-05-17 2000-09-29 ANTI-ANGIOGENIC PEPTIDES WITH LONG-TERM ACTION
SM200000031A SM200000031A (en) 1999-05-17 2000-10-09 Prolonged effect antiangiogenic peptides
US11/350,703 US7741286B2 (en) 1999-05-17 2006-02-08 Long lasting anti-angiogenic peptides
US12/759,153 US20110071082A1 (en) 1999-05-17 2010-04-13 Long lasting anti-angiogenic peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134,406 1999-05-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US62354300A A-371-Of-International 1999-05-17 2000-09-05
US11/350,703 Continuation US7741286B2 (en) 1999-05-17 2006-02-08 Long lasting anti-angiogenic peptides

Publications (2)

Publication Number Publication Date
WO2000070665A2 WO2000070665A2 (en) 2000-11-23
WO2000070665A3 true WO2000070665A3 (en) 2001-04-19

Family

ID=22463240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000763 Ceased WO2000070665A2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides

Country Status (9)

Country Link
EP (1) EP1171582A2 (en)
JP (3) JP4209086B2 (en)
CN (2) CN101289500A (en)
AU (1) AU764103B2 (en)
CA (1) CA2373252C (en)
SM (1) SM200000031A (en)
TW (1) TWI300414B (en)
WO (1) WO2000070665A2 (en)
ZA (2) ZA200106676B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307148B2 (en) 2004-04-23 2007-12-11 Conjuchem Biotechnologies Inc. Method for purification of albumin conjugates

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
ES2307718T3 (en) 2001-02-16 2008-12-01 Conjuchem Biotechnologies Inc. PEPTIDE 2 SIMILAR TO FLUCAGON (GLP-2) OF PROLONGED DURATION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS.
ATE295370T1 (en) 2001-05-31 2005-05-15 Conjuchem Inc LONG-ACTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION
JP2006514607A (en) * 2002-07-31 2006-05-11 コンジュケム，インコーポレーテッド Long-lasting sodium excretion increasing peptide derivative
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
CN103897031A (en) * 2012-12-25 2014-07-02 深圳先进技术研究院 Chemically modified thymopentin and synthetic method thereof
CN104892725A (en) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 Novel naphthalene acetamide compound
CN109503700A (en) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 The blood vessel formation inhibitor IIM 3-1 of maleimide base group modification and its application
CN110372781B (en) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 Preparation method and application of Enfuvirtide
CN117186187B (en) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 Anti-respiratory syncytial virus membrane fusion inhibitor and pharmaceutical application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290A1 (en) * 1992-12-04 1994-06-22 Philippe Pouletty Cellular drug anchors
WO1997023500A1 (en) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
WO1999024075A2 (en) * 1997-11-07 1999-05-20 Conjuchem, Inc. Affinity markers for human serum albumin
WO1999024074A2 (en) * 1997-11-07 1999-05-20 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2000004052A2 (en) * 1998-07-16 2000-01-27 Adprotech Limited Soluble derivatives of anti-angiogenic peptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290A1 (en) * 1992-12-04 1994-06-22 Philippe Pouletty Cellular drug anchors
WO1997023500A1 (en) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
WO1999024075A2 (en) * 1997-11-07 1999-05-20 Conjuchem, Inc. Affinity markers for human serum albumin
WO1999024074A2 (en) * 1997-11-07 1999-05-20 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2000004052A2 (en) * 1998-07-16 2000-01-27 Adprotech Limited Soluble derivatives of anti-angiogenic peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307148B2 (en) 2004-04-23 2007-12-11 Conjuchem Biotechnologies Inc. Method for purification of albumin conjugates

Also Published As

Publication number Publication date
JP2003500341A (en) 2003-01-07
EP1171582A2 (en) 2002-01-16
WO2000070665A2 (en) 2000-11-23
JP4209086B2 (en) 2009-01-14
AU4774800A (en) 2000-12-05
TWI300414B (en) 2008-09-01
AU764103B2 (en) 2003-08-07
JP2009143941A (en) 2009-07-02
JP2008110986A (en) 2008-05-15
SM200000031B (en) 2001-11-21
ZA200109110B (en) 2002-06-13
CN101289500A (en) 2008-10-22
ZA200106676B (en) 2002-07-19
CA2373252A1 (en) 2000-11-23
TW200524957A (en) 2005-08-01
CA2373252C (en) 2007-08-07
SM200000031A (en) 2001-11-21
CN1698881A (en) 2005-11-23

Similar Documents

Publication Publication Date Title
SI1180121T1 (en) Long lasting insulinotropic peptides
EP1329458A3 (en) Peptides that lower blood glucose levels
WO2005081711A3 (en) Monomethylvaline compounds capable of conjugation to ligands
WO2006081249A8 (en) Conjugates of biologically active proteins having a modified in vivo half-life
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
EP1623994A3 (en) Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
HK1049283A1 (en) Amphiphilic polymers and polypeptide conjugates comprising same
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
WO2000058466A3 (en) Protease resistant flint analogs
WO2001068676A3 (en) Lhrh-antagonists, production and use thereof as medicament
WO2004029075A3 (en) Peptide nucleic acids having improved uptake and tissue distribution
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2001042423A3 (en) Compositions and methods for detecting stress-inducible proteins
TNSN00190A1 (en) ANTI-ANGIOGENIC PEPTIDES WITH LONG-TERM ACTION
AU3553700A (en) Preparation for the treatment of pigmentation disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09623543

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2373252

Country of ref document: CA

Ref country code: CA

Ref document number: 2373252

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000929748

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 619018

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 47748/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000929748

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000929748

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 47748/00

Country of ref document: AU